Quick Answer
Intellia Therapeutics, Inc. reported Cash and Equivalents of $155.46 million for fiscal year 2025.
Intellia Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $155.46M | -17.8% |
| 2024 | $189.18M | -16.6% |
| 2023 | $226.75M | -56.7% |
| 2022 | $523.51M | +324.2% |
| 2021 | $123.41M | -22.9% |
| 2020 | $160.02M | +179.6% |
| 2019 | $57.23M | -2.8% |
| 2018 | $58.86M | -82.7% |
| 2017 | $340.68M | +24.8% |
| 2016 | $273.06M | +260.2% |
| 2015 | $75.82M | +670.1% |
| 2014 | $9.85M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $193.39M | +60.5% | +23.8% |
| June 30, 2025 | $156.17M | +19.4% | +23.1% |
| March 31, 2025 | $126.88M | -26.2% | -32.9% |
| December 31, 2024 | $189.18M | -16.6% | +57.0% |
| September 30, 2024 | $120.50M | -28.3% | -7.9% |
| June 30, 2024 | $130.85M | -23.8% | -23.9% |
| March 31, 2024 | $171.98M | -41.5% | -24.2% |
| December 31, 2023 | $226.75M | -56.7% | +34.9% |
- Intellia Therapeutics, Inc. showed a decrease of -17.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2014–2025 period, Intellia Therapeutics, Inc.’s cash and equivalents has grown by 1479.1% (from $9.85 million to $155.46 million).
- The most recent figure is from Intellia Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: